| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.042 | 0.5 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.5 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.025 | 0.5 |